Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
AtriCure Sees Unusually High Options Volume (NASDAQ:ATRC)
10:34am, Tuesday, 14'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) was the target of some unusual options trading activity on Monday. Stock investors purchased 1,500 call options on the company. This represents an increase of approximately
Goldman Sachs Group Inc. Trims Position in AtriCure Inc. (NASDAQ:ATRC)
08:36am, Tuesday, 14'th Apr 2020
Goldman Sachs Group Inc. decreased its stake in AtriCure Inc. (NASDAQ:ATRC) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange C
AtriCure (NASDAQ:ATRC) Price Target Cut to $41.00 by Analysts at Canaccord Genuity
07:25am, Tuesday, 14'th Apr 2020
AtriCure (NASDAQ:ATRC) had its price target reduced by Canaccord Genuity from $51.00 to $41.00 in a report released on Monday morning, BenzingaRatingsTable reports. Canaccord Genuity currently has a b
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Atricure (ATRC)
01:46pm, Monday, 13'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Atricure (ATRC) with bullish
Analysts Offer Insights on Healthcare Companies: PolarityTE (NASDAQ: PTE) and Atricure (NASDAQ: ATRC)
01:46pm, Monday, 13'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (
PTE
–
Research Report
) and Atricure (
ATRC
–
Research Report
) with bullish sentiment
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial hav
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
10:06am, Monday, 13'th Apr 2020
In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC), with a price target of $41.00. The
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
10:06am, Monday, 13'th Apr 2020
In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC – Research Report),
Diversified Trust Co Purchases Shares of 7,725 AtriCure Inc. (NASDAQ:ATRC)
09:56am, Monday, 13'th Apr 2020
Diversified Trust Co purchased a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional inv
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $41
12:00am, Monday, 13'th Apr 2020Insider Selling: AtriCure Inc. (NASDAQ:ATRC) SVP Sells $350,000.00 in Stock
08:56am, Sunday, 12'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $35.00, for a total tra
AtriCure Inc. (NASDAQ:ATRC) Shares Bought by Bank of America Corp DE
10:46am, Saturday, 11'th Apr 2020
Bank of America Corp DE lifted its position in AtriCure Inc. (NASDAQ:ATRC) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. T
Mark A. Collar Sells 4,000 Shares of AtriCure Inc. (NASDAQ:ATRC) Stock
10:02am, Saturday, 11'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) Director Mark A. Collar sold 4,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $36.07, for a total
AtriCure Inc. (NASDAQ:ATRC) Shares Purchased by Bank of New York Mellon Corp
09:14am, Saturday, 11'th Apr 2020
Bank of New York Mellon Corp boosted its stake in AtriCure Inc. (NASDAQ:ATRC) by 2.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 322,206 shares of the medical device compa
Q1 2020 Earnings Estimate for AtriCure Inc. Issued By Oppenheimer (NASDAQ:ATRC)
05:34am, Friday, 10'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) – Stock analysts at Oppenheimer issued their Q1 2020 earnings per share estimates for AtriCure in a report released on Monday, April 6th. Oppenheimer analyst S. Kalia for
